Spots Global Cancer Trial Database for asa404
Every month we try and update this database with for asa404 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma | NCT01071928 | Urothelial Carc... | Docetaxel ASA404 | 18 Years - | Hoosier Cancer Research Network | |
| An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404 | NCT01240642 | Metastatic Canc... Metastatic Canc... | ASA404 | 18 Years - | Novartis | |
| ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer | NCT00662597 | Non-Small Cell ... | ASA404 Placebo carboplatin Paclitaxel | 18 Years - | Novartis | |
| An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function | NCT01278849 | Histologically-... | ASA404 | 18 Years - | Novartis | |
| A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors | NCT01299701 | Advanced Solid ... | ASA404 | 18 Years - | Novartis | |
| An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function | NCT01278849 | Histologically-... | ASA404 | 18 Years - | Novartis | |
| ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors | NCT01031212 | Tumors | ASA404 Cetuximab Carboplatin Paclitaxel | 18 Years - | University of California, San Francisco | |
| An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404 | NCT01240642 | Metastatic Canc... Metastatic Canc... | ASA404 | 18 Years - | Novartis | |
| A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer | NCT00738387 | Non-Small Cell ... | ASA404 Placebo docetaxel | 18 Years - | Novartis | |
| A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors | NCT01299701 | Advanced Solid ... | ASA404 | 18 Years - | Novartis | |
| Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma | NCT01071928 | Urothelial Carc... | Docetaxel ASA404 | 18 Years - | Hoosier Cancer Research Network | |
| A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors | NCT01299701 | Advanced Solid ... | ASA404 | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
